Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of ritlecitinib in adults with nonsegmental vitiligo
2022-502518-98-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in nonsegmental vitiligo (3 arms), sponsored by Pfizer. Primary endpoints: F-VASI75 at Week 52, Treatment-emergent adverse events and 2 more. Planned start Apr 2024; status: authorised.
02
Drugs
ritlecitinib tosilate
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on 2022-502518-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502518-98-00.